Senan Sultan is an Endocrinology/Metabolic physician. OpenAlex indexes 19 publications with 1,275 citations (h-index 11).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
915 W Monroe St Ste 200
Jacksonville, FL 322041177
Telephone
904-384-2240Provider last certified this registry record 4 Feb 2025.
Industry payments
53 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year202520 payments
- Dexcom, Inc.Program year202516 payments
- Medtronic, Inc.Program year202518 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
69.5%Insulin Analog25.2%Lantus Solostar21%Novolog Flexpen13%Tresiba Flextouch U-10012%Humalog Kwikpen U-10011%Tresiba Flextouch U-2009%Levemir Flexpen4%Novolog4%Insulin Lispro Kwikpen U-1004%Humalog3%Basaglar Kwikpen U-1003%Toujeo Solostar3%Soliqua 100-332%Fiasp Flextouch2%Lantus2%Humalog Kwikpen U-2002%Insulin Aspart Flexpen2%Toujeo Max Solostar1%Insulin Lispro1%Xultophy 100-3.61%Part D<11 patientsGLP-1 receptor agonist15.3%Ozempic63%Mounjaro21%Trulicity11%Rybelsus5%Part D≥125 patients+ 11 more classes in this area
Hormonal (systemic)
18.3%l-Thyroxine15.4%Levothyroxine Sodium86%Synthroid12%Unithroid2%Part D<11 patientsThyroid Hormone Synthesis Inhibitor2.4%Methimazole100%Part D≥36 patients+ 1 more class in this area
Cardiovascular
7.6%Statin4.8%Atorvastatin Calcium37%Simvastatin29%Rosuvastatin Calcium22%Pravastatin Sodium13%Part D<11 patientsACE inhibitor0.7%Lisinopril100%Part D≥13 patients+ 5 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial
American Journal of Kidney Diseases
2023 - FRI667 Profound And Persistent Hypoglycemia With Hepatocellular Carcinoma- A Non-islet Cell Tumor
Journal of the Endocrine Society
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”